Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

In imported Lay's chips, traces of six allergens were found at once, which the manufacturer did not inform about on the ...

Shares of Akero Therapeutics ($AKRO) skyrocketed on Monday following game-changing results from its lead drug, efruxifermin, ...

One of the standout projects making waves in this space is Monsta Mash, a GameFi ecosystem that is drawing significant attention from large investors due to its incredibly low entry price of $0.00365.

It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Faculty and coaches from three campuses of Commonwealth University will vote anonymously in February to give their voice in ...

Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.

Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...